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Hydroxy-naphthoquinones are competitive inhibitors of the cytochrome bc1 complex that bind to the ubiquinol oxidation site between
cytochrome b and the iron–sulfur protein and presumably mimic a transition state in the ubiquinol oxidation reaction catalyzed by the enzyme.
The parameters that affect efficacy of binding of these inhibitors to the bc1 complex are not well understood. Atovaquone®, a hydroxy-
naphthoquinone, has been used therapeutically to treat Pneumocystis carinii and Plasmodium infections. As the pathogens have developed
resistance to this drug, it is important to understand the molecular basis of the drug resistance and to develop new drugs that can circumvent the
drug resistance. We previously developed the yeast and bovine bc1 complexes as surrogates to model the interaction of atovaquone with the bc1
complexes of the target pathogens and human host. As a first step to identify new cytochrome bc1 complex inhibitors with therapeutic potential
and to better understand the determinants of inhibitor binding, we have screened a library of 2-hydroxy-naphthoquinones with aromatic, cyclic,
and non-cyclic alkyl side-chain substitutions at carbon-3 on the hydroxy-quinone ring. We found a group of compounds with alkyl side-chains that
effectively inhibit the yeast bc1 complex. Molecular modeling of these into the crystal structure of the yeast cytochrome bc1 complex provides
structural and quantitative explanations for their binding efficacy to the target enzyme. In addition we also identified a 2-hydroxy-naphthoquinone
with a branched side-chain that has potential for development as an anti-fungal and anti-parasitic therapeutic.
© 2007 Elsevier B.V. All rights reserved.Keywords: Hydroxy-naphthoquinones; Cytochrome bc1 complex; Malaria; Plasmodium; Pneumocystis; Atovaquone1. Introduction
Atovaquone is a substituted hydroxy-naphthoquinone (2-
[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naph-
thoquinone) that binds tightly and competitively to the ubi-
quinol oxidation site of the cytochrome bc1 complex [1]. This
inhibitor was first used therapeutically as an anti-malaria
compound with broad spectrum activity against apicomplexan
parasites [2–4] and later was also shown to prevent and clear
Pneumocystis jirovecii pneumonia [5,6]. However, the patho-
gens soon developed resistance to the drug, and it was shown
that the resistance was due to mutations in the gene for⁎ Corresponding author. Tel.: +1 603 650 1621.
E-mail address: Trumpower@Dartmouth.edu (B.L. Trumpower).
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doi:10.1016/j.bbabio.2007.02.014cytochrome b, a subunit that forms part of the ubiquinol oxi-
dation site of the cytochrome bc1 complex [7]. As the yeast
bc1 complex is also inhibited by atovaquone, we have deve-
loped the yeast Saccharomyces cerevisiae as a model to
explain atovaquone resistance in P. jirovecii [8], Plasmodium
falciparum [9] and Toxoplasma gondii [10].
In the current study, we have extended the use of the yeast
bc1 complex model by combining inhibitor titrations and
computer modeling calculations to understand the structural
parameters that affect efficacy of binding of 2-hydroxy-
naphthoquinones to the bc1 complex. We first screened a
randomly chosen library of 2-hydroxy-naphthoquinones with
aromatic, cyclic, and non-cyclic alkyl side-chains at position 3
on the hydroxy-quinone ring for inhibition of bc1 complex
activity. We then tested a series of 2-hydroxynaphthoquinones
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a quantitative structure/activity relationship based on side-chain
length. We also evaluated the relative efficacy of two
stereoisomers with a branched side-chain. The results of these
comparisons provide a starting point to synthesize new
hydroxy-naphthoquinone inhibitors of the bc1 complex with
potential therapeutic uses.
2. Experimental procedures
2.1. Materials
Dodecylmaltoside was obtained from Roche Applied Science. DEAE-
Biogel A was obtained from Bio-Rad. Diisopropylfluorophosphate, decyl
ubiquinone and dithionite were purchased from Sigma. Stigmatellin was
purchased from Fluka Biochemica. Atovaquone was a gift from GlaxoSmithK-
line. A collection of 2-hydroxy-1,4-naphthoquinones with aromatic, cyclic, and
non-cyclic alkyl side-chains was obtained from the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis of the National Cancer Institute. The hydroxy-1,4-
naphthoquinones were dissolved in dimethyl sulfoxide at 2 mM concentration
and stored at −20 °C.
2.2. Synthesis of naphthoquinones
The synthesis of 3-alkyl-2-hydroxy-1,4-naphthoquinones exploits radical
alkylation of commercial 2-hydroxy-1,4-naphthoquinone with alkyl iodides in
the presence of tributyltin hydride and 2,2′-azobisisobutyronitrile as radical
initiator [11]. PhSO2- protection with PhSO2Cl/K2CO3 in DMF gave 66% yield
of the O-protected product. Chiral (S)- and (R)-2-methyloctyl iodides were
prepared in accordance with the known sequence [12–14], which started from
methyl-(R)- or (S)-3-hydroxy-2-methylpropionate correspondingly and
included copper catalyzed cross coupling of alkyltosylate and Grignard reagent
as a key step [15]. The synthesized chiral iodides were then used for radical
alkylation.
2.3. Purification of cytochrome bc1 complexes
Cytochrome bc1 complexes from yeast and bovine heart were isolated from
mitochondrial membranes as described previously [16,17].
2.4. Ubiquinol-cytochrome c reductase activity measurements
Cytochrome c reductase activity was assayed in 50 mM potassium
phosphate, pH 7.0, 250 mM sucrose, 0.2 mM EDTA, 1 mM NaN3, 2.5 mM
KCN, 0.01% Tween-20 and 40 μM cytochrome c at 23 °C. The cytochrome
bc1 complex was diluted to 2.5 nM in the assay buffer, inhibitor was added to
the assay mixture and allowed to stir with the enzyme for 1 min, after which
the reaction was started by adding 2,3-dimethoxy-5-methyl 6-decyl-1,4-
benzoquinol, an analogue of ubiquinol. Reduction of cytochrome c was
monitored in an Aminco DW-2a spectrophotometer at 550 versus 539 nm in
dual wavelength mode. Data were collected and analyzed using an Online
Instrument Systems Inc. computer interface and software. IC50 values for
compounds that were inhibitory at concentrations less than 200 nM were
determined from titration curves of inhibitor concentration versus activity.
Relative amounts of the chiral isomers in the racemic mixture of compound
#10576 were calculated from the IC50 values of the two isomers and that of the
mixture using the equation X/IC50(S)+Y/IC50(R)=1/IC50(M) where X+Y=1.0.
2.5. Molecular modeling
Molecular modeling was carried out on Silicon Graphics O2 and Octane
workstations using the commercially available Insight II® software package
(Acclerys Inc., San Diego). The starting structure was the energy-minimized
atovaquone-liganded yeast cytochrome bc1 complex [1]. Briefly, a minimizedconformation of atovaquone was docked into a stigmatellin liganded crystal
structure [18] that was modified to include the rotation of Glu-272 and a water
mediated hydrogen bond observed in the nHDBT liganded crystal structure [19].
For the structures shown here, the initial docking was achieved by overlay of the
hydroxynaphthoquinone ring with the one from the previously calculated
atovaquone structure. The initial position of the linear aliphatic side-chain, prior
to the molecular dynamics run, followed the one observed in the nHDBT crystal
structure.
For the molecular dynamics calculations, a set of restraints was set up
between the hydroxy-naphthoquinones, His-181 of the Rieske protein, and Glu-
272 of cytochrome b in order to maintain the ligand in position during the
dynamic stages. The naphthoquinones and cytochrome b residues within 4.0 Å
were allowed to be flexible. A surrounding 9.5 Å shell of residues in both
cytochrome b and the iron–sulfur protein was fixed, and the most distant
residues were excluded from the calculation in order to obtain a manageable
simulation speed. A 9.5 Å atom-based cut-off for nonbonding interactions was
used during the calculations, with the dielectric constant set at 2.0. Eight
simulated annealing runs were performed, each from 800 to 298 K, with five
temperature steps and a simulation time of 5000 fs/step. The Nose temperature
control method was used with a 0.5 fs/iteration time step. A custom macro was
written to select the lowest energy structure from each dynamics run for
continued modeling. Between each dynamics run, a minimization of 250
iterations was performed. After the final round of molecular dynamics, the
lowest energy structure was minimized to a final convergence criterion of 0.001,
using Cauchy's steepest descent method as implemented in the Discover 3®
module within the Insight II® software, followed by conjugate gradient and
Newton methods in succession. Of the eight minimized results obtained, the
three lowest energy structures were chosen for binding energy calculation.
The binding energy calculation was adapted from a previous method [8]
and uses a common subset that included the naphthoquinone and cytochrome
b residues within 4.0 Å of the inhibitor. The reported value for each
naphthoquinone is an average of the three calculated lowest energy structures
and contains non-bonding interactions (van der Waals and electrostatic) as
well as internal conformational energies of the ligand and adjacent pocket
residues.3. Results
3.1. Inhibition of bovine and yeast bc1 complexes by linear
alkyl Naphthoquinones
The molecular target of the hydroxy-naphthoquinone
inhibitors is known to be the ubiquinol oxidation pocket at
the center P site of the cytochrome bc1 complex [1]. We thus
tested a library of approximately 60 2-hydroxy-naphthoqui-
nones for inhibition of ubiquinol-cytochrome c reductase
activity of both yeast and bovine cytochrome bc1 complexes.
The compounds tested included derivatives with aromatic,
cyclic non-aromatic, branched and linear side-chains at the
carbon-3 position of the hydroxy-quinone ring. The results of
this initial survey are summarized in Supplemental Data
Table 1, which also includes the structures of the tested
compounds. Most of these compounds were found to show
no or very poor bc1 complex inhibition and were not studied
further.
A small group of alkyl hydroxy-naphthoquinones displayed
significant inhibition of enzymatic activity. We thus synthesized
the remaining compounds of the series with linear side-chains of
varying length for a more systematic study of the structure/
activity relationship in this group of inhibitors. All members of
the linear series inhibited both yeast and bovine cytochrome bc1
complex activities. As can be seen from the data in Fig. 1, the
Fig. 1. Effect of chain length on inhibition of bovine and yeast cytochrome bc1
complexes by 2-hydroxy-naphthoquinones with linear alkyl side-chains. The
IC50 values for inhibition of the bc1 complex activity is shown with light gray
bars for the yeast enzyme and dark bars for the bovine enzyme.
Fig. 2. Inhibition of bovine and yeast cytochrome bc1 complexes by 2-hydroxy-
naphthoquinones with 8-carbon linear alkyl chain and stereoisomers of a methyl
substituted 8-carbon branched alkyl chain. The IC50 values for inhibition of the
bc1 complex activity are shown with light gray bars for the yeast enzyme and
dark bars for the bovine enzyme. The structure of the branched chain 2-hydroxy-
naphthoquinone (compound #10576) is shown above the bar graphs.
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great as that of the bovine enzyme with any given compound.
The IC50 values with both bc1 complexes show that a linear
alkyl chain of at least 8 carbons is required to achieve significant
enzymatic inhibition with IC50 values below 100 nM. The best
IC50 values obtained with the yeast enzyme were with the C8/C9
side-chains whereas the C9/C10 side-chains were the most
effective with the bovine bc1 complex. For both species, a slight
decrease in binding was observed when the linear alkyl chain
was longer than C10.
3.2. Differential binding of a branched alkyl Naphthoquinone
to bovine and yeast bc1 complexes
The branched 3-alkyl 2-hydroxy-naphthoquinones inclu-
ded in the library did not show significant inhibition of bc1
activity except for the compound #10576. This hydroxy-
naphthoquinone contains an 8-carbon branched side-chain
with a methyl group on the second carbon of the side-chain
from the quinone ring. The IC50 for inhibition of the yeast
enzyme by this branched side-chain hydroxy-naphthoqui-
none dropped markedly from 80 nM to 15 nM when
compared to the linear 8-carbon chain, while the inhibition
of the bovine enzyme remained the same with the two
compounds (Fig. 2).
Because the methyl group in this position creates an
asymmetric carbon, we speculated that the compound obtainedfrom the National Cancer Institute collection would be a
racemic mixture and that one of the stereoisomers might
display even better inhibition properties. We thus synthesized
the R (R-10576) and S (S-10576) stereoisomers of #10576 as
described above. Accordingly, a further drop of the IC50 from
15 nM to 6 nM was observed with the S isomer of #10576, as
would be expected if the racemic mixture of the original batch
contained approximately equal amounts of the two isomers.
From the measured IC50 values of the R and S isomers and of
the mixture, it can be estimated that the mixture contains
approximately 45±5% S isomer. The IC50 value for the yeast
enzyme was about 28 times lower with the S than with the R
stereoisomer and confirmed the strong stereo-selectivity of the
binding pocket for this class of compound. Interestingly, the
side-chain of R-10576 resulted in weaker inhibition of both
yeast and bovine enzymes (with IC50 of 170 nM and 420 nM)
than the unbranched 8-carbon chain derivative (80 nM and
190 nM).
In order to compare the efficacy of inhibitors with the
bovine and yeast bc1 complexes, we defined the “Selectivity
Coefficient” of an inhibitor as the IC50 obtained with the
bovine enzyme divided by the IC50 obtained with the yeast
enzyme. The Selectivity Coefficients for the linear 8 carbon
chain naphthoquinones, atovaquone, myxothiazol, and the R
and S stereoisomers of #10576 are show in Fig. 3. Contrary to
myxothiazol, the linear 8-carbon chain naphthoquinone, and
the R isomer of #10576, which displayed poor enzyme
selectivity, atovaquone and the S isomer of #10576 showed
high Selectivity Coefficients. Notably, the selectivity of S-
10576 was approximately 3 times higher than that recorded for
atovaquone.
Fig. 4. Overlaid view of the calculated structures of short (A) and long (B) linear
alkyl side-chain naphthoquinones docked into the yeast cytochrome bc1
complex. Amino acids in the cytochrome b binding pocket are labeled and
their carbon atoms are green, nitrogen atoms are blue and oxygen atoms are red.
The hydroxy-naphthoquinones with linear alkyl chains containing 4 carbons
(white), 6 carbons (yellow), 8 carbons (cyan), 9 carbons (orange), 10 carbons
(magenta) and 11 carbons (blue) are shown.
Fig. 3. Selectivity of 2-hydroxy-naphthoquinone inhibitors of the bovine and
yeast cytochrome bc1 complexes. The bar graphs show the Selectivity
Coefficients for inhibition of the yeast versus bovine bc1 complex by the 2-
hydroxy-naphthoquinone with an 8-carbon linear alkyl side-chain (C8), both R
and S stereoisomers of compound #10576 (C8+1R and C8+1S), and
atovaquone (ATV). The value for myxothiazol (Myx), a non-quinoid inhibitor,
is also shown.
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Naphthoquinones docked in the yeast cytochrome bc1 complex
All members of the linear hydroxy-naphthoquinone series
and both stereoisomers of #10576 were docked into the
ubiquinol oxidation pocket at the center P site of the yeast bc1
complex. We used a previously modeled atovaquone-bound
structure [7] as a starting point for calculating the lowest energy
conformations of the docked ligands. The results of these
docking experiments are overlaid in Figs. 4 and 5. Like
atovaquone, the hydroxyl group of the hydroxy-naphthoqui-
nones binds via a hydrogen bond to the nitrogen of His-181 of
the Rieske iron–sulfur protein. On the opposite side of the ring
system the carbonyl group at position 4 of the quinone ring
forms a water-mediated hydrogen bond with Glu-272 of
cytochrome b. The bulk of the intermolecular interactions
between the naphthoquinones and the cytochrome b are
essentially hydrophobic. The side-chains freely interact with a
network of aromatic and aliphatic side-chains of the cytochrome
b including Leu-282, Leu-275, Ile125, Phe-296, Ile-147, Leu-
150 and Phe-151.
With the linear alkyl series of hydroxy-naphthoquinones, we
observed that the shortest side-chains, containing 6 or fewer
carbons, did not fully optimize the intermolecular hydrophobic
interaction within the binding pocket. As can be seen in Fig. 4A,
these side-chains remained in an extended, straight position at
all stages of the dynamics and minimization process (Fig. 4A).
By contrast, the calculated structures obtained with the longer
chains, containing 8 or more carbons in the side-chain,
displayed bended features (Fig. 4B) that were similar to the
bending of the ligand observed in the stigmatellin-bound
structure [18].
Docking and energy minimization of the stereoisomers of
#10576 into the binding pocket at the center P site of the yeast
bc1 complex generated two different calculated structures that
are superimposed in Fig. 5. The 8-carbon chain of the S stereo-isomer mostly followed the same binding groove as the
previously described linear octyl derivative. The side-chain is
bent and fully interacts with the cytochrome b (Fig. 5, blue
chain). Closer examination of the calculated structure of this
stereoisomer reveals that the branched methyl group, by its
strong hydrophobic interaction with the Val-146 residue,
constrains the rotation of the loose end of the side-chain into
the binding groove. The branched methyl group of the R
stereoisomer displays the same interaction with the Val-146
residue, but because of steric constraints, the chain cannot bend
and shows a straight conformation similar to the short linear
derivatives (Fig. 5, yellow chain). In order to accommodate the
bulk of this straight chain, the calculated structure has to
significantly rotate the position of the side-chains of the
Fig. 5. Overlaid view of the calculated structures of the R and S stereoisomers of
compound #10576 docked into the yeast cytochrome bc1 complex. The carbon
atoms of the cytochrome b binding pocket amino acid residues are green,
nitrogen atoms are blue, oxygen atoms are red, and sulfur atom is yellow. The R
(yellow) and S (cyan) stereoisomers of compound #10576 are shown, and the
modified positions of the side-chains of the residues Met-295 and Phe-296
(purple) are also shown.
Fig. 6. Experimentally measured IC50 values compared to calculated binding
energies of naphthoquinones with linear alkyl side-chains in the yeast
cytochrome bc1 complex. The IC50 values for inhibition of the yeast bc1
complex activity are shown with light gray bars. The dark bars show the
calculated changes in binding energy.
Fig. 7. Experimentally measured IC50 values compared to calculated binding
energies of the naphthoquinone with an 8 carbon linear alkyl side-chain and the
R and S stereoisomers of compound #10576 in yeast cytochrome bc1 complex.
The IC50 values for inhibition of the yeast bc1 complex activity are shown with
light gray bars. The dark bars show the calculated changes in binding energy.
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residues).
3.4. Calculation of binding energy of linear and branched alkyl
Naphthoquinones to the yeast cytochrome bc1 complex
The energy required for binding of the linear side-chain
naphthoquinones was calculated for each of the modeled
structures. The calculated binding energies were then compared
with the experimentally measured IC50 values. The relative
increase in calculated binding energies correlated well with the
relative increase in IC50 values for the yeast bc1 complex for
each linear alkyl side-chain derivative as shown in Fig. 6. A
slight difference was observed for the longest linear chains, for
which the calculation predicted an increased binding instead of
the observed decrease. Possible reasons for this difference are
discussed below.
A similar graphic comparison was plotted using the
calculated binding energies extracted from the modeled
structures of the #10576 stereoisomers and the experimentally
measured IC50 values obtained with these branched naphtho-
quinones. As with the linear series, there was a good correlation
observed between the two sets of data as shown in Fig. 7.
4. Discussion
Atovaquone is a hydroxy-naphthoquinone that has been used
therapeutically against parasites and pathogenic fungi and that
acts by inhibiting the cytochrome bc1 complex [1]. Sponta-
neously arising mutations in the cytochrome b gene were
genetically linked to drug resistance in the pathogens, but it was
not possible to isolate the cytochrome bc1 complex from these
organisms to confirm the molecular basis of the drug resistance.Because the yeast cytochrome bc1 complex is also inhibited
by atovaquone, we have previously developed S. cerevisiae as a
model to study cytochrome b mutations conferring atovaquone
resistance in Pneumocystis [8], Plasmodium [9], and Toxo-
plasma [10] species. In those studies, using structures of the
yeast bc1 complex co-crystallized with various inhibitors
[18,19] as a starting point, we were able to design a coherent
computer model of the interactions between the drug and its
target. This virtual model of atovaquone binding was validated
by strong correlations between the experimental measurements
of atovaquone resistance in the mutated yeast enzymes and the
calculated drug binding energies. An overlay of these crystal
structures with our modeled structures (Fig. 8) shows how the
hydroxy-naphthoquinones share common features with stigma-
tellin, such as the bended position of the chains, and nHDBT,
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none ring and a similar position of the short alkyl side-chain.
In the current study, we have used this set of tools to screen a
small library of hydroxy-naphthoquinones that included a wide
variety of linear, branched, saturated, unsaturated and aromatic
substitutions in position 3 of the quinone ring (see Supplemental
Data Table 1). Most of these compounds, including derivatives
known for their anti-tumor [20] and anti-leishmanial [21]
activities, were found to have no or very poor bc1 complex
inhibition activity and were not studied further. Of the re-
maining set, approximately half of the compounds were
suspected as likely to be toxic for humans and discarded
because of a better inhibition of the bovine bc1 complex than of
the yeast enzyme.
The linear alkyl side-chain derivatives displayed significant
inhibition of the yeast enzyme although they did not exhibit
significant species selectivity. Molecular modeling revealed that
the longer the side-chain, the greater the hydrophobic interac-
tion between the inhibitor and the binding pocket of the
cytochrome b (Fig. 4B). Calculation of the binding energy for
these compounds was correlated by titrations of their inhibitory
activity with the yeast enzyme, except for the 4-carbon side-Fig. 8. Binding of different inhibitors to the ubiquinol oxidation pocket at center P of
compared by overlays of the two inhibitors in panels A and B, with stigmatellin c
stigmatellin (18) and nHDBT (19) were constructed from the coordinates of the crysta
(ATV) and the S isomer of #10576 is compared by overlays of the two inhibitors in pan
atom in panel D. When colored, oxygen atoms are red, carbons are green, sulfur is y
shown as yellow and blue ribbons, respectively, and His-181 of the Rieske protein
cytochrome b is oriented toward stigmatellin and forms a hydrogen bond directly to t
Glu-272 is rotated away from the inhibitor, and a water molecule forms hydrogen bo
hydroxynaphthoquinone inhibitors and the backbone nitrogen of Glu-272.chain compound (Fig. 6). This discrepancy can be explained by
the set of restraints that was included in the modeling in order to
maintain low affinity ligands in the binding pocket during the
high temperature annealing runs of the dynamics stage.
The drug atovaquone has been known for poor bioavail-
ability attributed to its poor solubility [22]. Although we did not
evaluate bioavailability, the size and hydrophobicity of the side-
chain impacted the aqueous solubility of the hydroxy-
naphthoquinones in the current study (data not shown). We
observed that saturated alkyl side-chain derivatives longer than
C9 are less effective with both yeast and bovine bc1 complexes
(Fig. 1). Because our molecular modeling could not incorporate
the solubility effect of these long side-chains, it usually
predicted slightly higher binding affinity for the naphthoqui-
nones with longer chains (e.g. C11) than the observed degree of
inhibition (Fig. 6).
It was observed that insertion of a methyl group in the beta
position of a saturated 8-carbon linear side-chain (compound
#10576) significantly impacted the inhibition efficacy, lowering
the IC50 more than five times when compared to the linear C8
side-chain. Of the various compounds that we tested during our
screening, this branched hydroxy-naphthoquinone exhibited thethe yeast cytochrome bc1 complex. Binding of stigmatellin (STG) and nHDBT is
olored by atom in panel A and nHDBT colored by atom in panel B. Views of
l structures of the yeast enzyme with the inhibitors bound. Binding of atovaquone
els C and D, with atovaquone colored by atom in panel C and #10576 colored by
ellow and nitrogen is blue. Portions of the Rieske protein and cytochrome b are
is also shown for perspective. In panel A the carboxyl group of Glu-272 of
he hydroxy-chromone ring of the inhibitor. In panels B–D the carboxyl group of
nds between a carbonyl oxygen on the quinone ring of the benzoxythiazole and
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the pure S stereoisomer of #10576 enhanced this inhibition even
further. Notably, this stereoisomer displayed a selectivity
toward the yeast enzyme three times greater than that exhibited
by the drug atovaquone. Molecular modeling of #10576
interaction with the yeast bc1 complex binding pocket shows
that both stereoisomers have the branched methyl group facing
in the same direction toward the Val-146 residue. However,
while this decrease in degrees of freedom of the side-chain was
thermodynamically advantageous for the S stereoisomer, it was
detrimental for docking of the other stereoisomer. The
calculated structure showed that the R stereoisomer clashed
with various residues of the binding pocket that were forced to
rotate in order to accommodate the more rigid conformation of
the R stereoisomer. The sharp increase in IC50 and calculated
binding energy between the linear C8 compound and the R
stereoisomer of #10576 can be explained by the high energetic
cost of this structural adjustment.
The selectivity observed with the S stereoisomer of #10576
for the yeast versus bovine bc1 complex can be rationalized by
structural differences in the binding site geometry as illustrated
in Fig. 9. The interaction between the inhibitor and the binding
pocket is maximal when the branched side-chain is sandwiched
between Leu-275 and Val-146. In the bovine enzyme, theFig. 9. Binding of the S isomer of #10576 in the ubiquinol oxidation pocket of the y
may contribute to differential binding efficacy. Panel A shows the van der Waals inte
the pocket. Panel B shows the corresponding Val-145 and Phe-274 in the pocket of th
inhibitor. Panel C shows the stabilizing interaction between Phe-278 and #10576 in th
is distant from the inhibitor as shown in Panel D. Protein ribbons and atoms of the am
and the equivalent His-161 of the bovine enzyme are shown for perspective.corresponding amino acid pair Phe-274 and Val-145 is less
effective, and a yeast enzyme with a L275F mutation [8]
displays a 4-fold increase of IC50 toward the S stereoisomer of
#10576 (data not shown). Furthermore, the Phe-278 present in
the yeast enzyme is important in locking the long chains in the
bent position where the inhibitor-binding pocket interactions are
maximized. In the bovine enzyme, the Ala-277 failed to restrict
the ligand into this conformation. Further evidence for the
contribution of this residue to the difference in binding is that a
yeast enzyme with a P278I mutation [9] also displays a 4-fold
increase of IC50 toward the S stereoisomer of #10576 (data not
shown). The cumulative effect of these differences, which affect
both enthalpic and entropic binding determinants, at least partly
accounts for the species selectivity.
The racemic mixture of compound #10576 has been known
for showing strong anti-plasmodium activity in an avian model
[23], and we expect that the S stereoisomer would probably
show even greater activity in this test system. Unfortunately,
this compound has also been shown to be rapidly metabolized in
humans by bis-hydroxylation of the terminal two carbons of the
side-chain, followed by oxidative decarboxylation, which
nullified its anti-plasmodium therapeutic potential [24,25].
This hydroxylation reaction, presumably catalyzed by human
cytochrome P450s, should be preventable by appropriateeast and bovine cytochrome bc1 complexes illustrating structure differences that
ractions between Val-146 and Leu-275 that facilitate stable binding of #10576 in
e bovine enzyme. Note the apparent lack of interaction between Phe-274 and the
e yeast enzyme, whereas Ala-277 in the equivalent position in the bovine enzyme
ino acids and the inhibitor are colored as in Fig. 8. His-181 of the yeast enzyme
326 J.J. Kessl et al. / Biochimica et Biophysica Acta 1767 (2007) 319–326modification of the branched side-chain. Since the S stereo-
isomer of #10576 is more potent and exhibits better selectivity
with a fungal enzyme than atovaquone, this compound should
be considered as a new lead to design an improved hydroxy-
naphthoquinone therapeutic.
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